|drug3628||Valsartan (Diovan) Wiki||0.71|
|drug3815||blood sampling Wiki||0.29|
|drug2557||Placebo oral tablet Wiki||0.13|
|D012127||Respiratory Distress Syndrome, Newborn NIH||0.13|
|D055371||Acute Lung Injury NIH||0.13|
|D012128||Respiratory Distress Syndrome, Adult NIH||0.11|
There are 2 clinical trials
The purpose of this study is to evaluate the efficacy and safety of intravenous abatacept administered to hospitalized COVID-19 participants with respiratory compromise.
This is a single-arm open label trial for hospitalized patients with COVID-19 (Coronavirus). The primary endpoint of the study is to assess the requirement for mechanical ventilation in patients who are admitted to the hospital with COVID-19 infection and a Pulse Oxygen Level = 93% on room air. The primary endpoint analysis will be performed using all enrolled patients.
Description: Cumulative incidence of mechanical ventilation-free survival at 30 days after initiation of abataceptMeasure: Mechanical ventilation-free survival Time: 30 days
Description: Number of days a patient is on a ventilator, if applicableMeasure: Duration of days on a ventilator Time: 30 days
Description: Number of days until patient recovers with SpO2 > 93%Measure: Days until pulse oxygen is > 93% on room air Time: 30 days
Description: No supplemental oxygen for at least 24 hoursMeasure: Days until supplemental oxygen is no longer required Time: 30 days
Description: Number of days until fever is less than 38°CMeasure: Duration of fever >= 38°C Time: 30 days
Description: Patient survival status through 90 daysMeasure: Overall survival Time: 90 days
Description: Number of Infusion Reactions in patients treated with abataceptMeasure: Infusion reactions Time: 14 days
Description: Number of Secondary infections in patients treated with abataceptMeasure: Secondary infections Time: 90 days
Description: Change in clinical status from baseline, as assessed by a 7-point ordinal scale on Day 14Measure: Change in Clinical Status, based on 7-point ordinal scale Time: 14 days
Description: Viral load at baseline and on Days 7, 14, 21, 28 (each +/- 2 days) after the first abatacept dose.Measure: Viral load Time: 28 days
Description: Improvement in lung findings based on CXR (chest x-ray)Measure: Radiographic Improvement Time: 14 days
Data processed on September 26, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.Drug Reports MeSH Reports HPO Reports